echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > Ibrain ultrasound-guided peripheral trunk block technology: a new approach that is gradually taking the stage of clinical anesthesia

    Ibrain ultrasound-guided peripheral trunk block technology: a new approach that is gradually taking the stage of clinical anesthesia

    • Last Update: 2022-09-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    In recent decades, nerve blocking techniques have been fully developed, thanks mainly to ultrasound in



    With the popularization and application of ultrasound in clinical anesthesia, the anatomical knowledge required for regional block anesthesia extends from spinal canal, nerve stem and other related structures to paravertebral structures, chest and abdominal wall muscles, muscle fascia planes, etc



    Peripheral nerve block is currently mainly used for postoperative analgesia, which occupies an important position in multimodal analgesia, which can effectively reduce the occurrence



    The development of peripheral stem nerve block also faces many challenges, the most critical and urgent clinical problem is how to prolong the duration



    In summary, ultrasound-guided peripheral stem nerve block has changed the management ideas and strategies



    Figure Thoracic nerve block

    Figure note: (1) trapezius muscle; (2) Rhomboid muscle; (3) Orthostatic spinal muscles; (4) anterior serratus; (5) External intercostal muscles; (6) Medial intercostal muscles; (7) The outermost muscles between the intercostals; (8) Latissimus dorsi; (9) Pectoralis minor muscles; (10) Pectoralis major muscles; (11) Transverse protrusions; (12) Spinous protrusions; (13) Pleura



    Scan the QR code to read the original text

    https://onlinelibrary.


    About Ibrain

    Ibrain is a global leader in research and education – Wiley publishes an English-language open access journal
    in the field of neuroscience hosted by the Affiliated Hospital of Zunyi Medical University.

    The journal is published about

    Cutting-edge research on the brain, spinal cord and nerves provides neuroscientists with a platform
    for basic and translational medicine and clinical practice.

    Ibrain is edited by Professor Wang Tinghua, Director of the Laboratory of Neurological Diseases at West China Hospital of Sichuan University, and Professor Xin-Fu Zhou of the University of South Australia
    .

    Journal publication scope and topics:

    Ibrain is interested in topics related to brain, spinal cord, and neurological diseases, including but not limited to clinical medicine, molecular diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology, and artificial intelligence
    .

    The journal focuses on clinical and experimental research advances, providing characterization, pathogenesis, diagnosis, treatment, medical innovations and technologies for brain, spinal cord and neurological diseases
    .

    Topics published in the journal include, but are not limited to:

    Types of journal articles published:

    • Original article

    • Reviews

    • Comments

    • Case reports

    • Letter

    • Methods

    Journals in 2022-2024 are exempt from publication fees (APCs
    ).

    Currently, Ibrain is included in the international search database DOAJ, and it takes only two months
    from the filing of the application to the time it is included in the DOAJ.

    We sincerely welcome researchers, doctors and graduate students in the field of neuroscience to actively submit articles to the journal!

    Special Issue Call for Papers

    Ibrain will publish a special issue publishing the latest basic and clinical research
    on CNS injury injection materials.

    It will focus on the molecular mechanisms of the use of injectable materials to repair brain injuries, basic and clinical studies of effective injection materials, and related topics
    .

    We cordially invite researchers to provide original research papers or review articles
    for this special issue.

    We can waive your publication fee and provide authors with fast access to
    publication.

    Special Issue Details:

    https://onlinelibrary.
    wiley.
    com/page/journal/27692795/themed-collections/injectable_materials

    Written by: Imperio

    Proofreading and Adaptation: Xiong Liulin, Tina

    Wiley is a global leader in research and education, inspiring human potential
    by facilitating discovery, empowering education, and shaping talent.

    For more than 200 years, Wiley has driven the development of a
    global knowledge ecosystem.

    Today, our high-impact content, platforms, and services help researchers, learners, institutions, and businesses achieve their goals
    in a rapidly changing world.

    Wiley, headquartered in Hoboken, New Jersey, USA, is listed on the New York Stock Exchange under the symbols WLY and WLYB
    .

    Like, watch, share, have a one-click triple!

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.